Last updated on August 2019

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis


Brief description of study

This study is being conducted to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). Participants will be treated with either placebo or one of the 4 dose regimens of GSK2330672 (20 milligram [mg], 90 mg or 180 mg taken once daily or 90 mg twice daily). Subjects on GSK2330672 will also receive placebo tablets to maintain blinding. The total duration of a subject's participation will be up to 45 days of screening and 24 weeks of study including follow-up.

Clinical Study Identifier: NCT02966834

Find a site near you

Start Over

GSK Investigational Site

Phoenix, AZ United States
  Connect »

GSK Investigational Site

Sacramento, CA United States
  Connect »

GSK Investigational Site

Miami, FL United States
  Connect »

GSK Investigational Site

Tampa, FL United States
  Connect »

GSK Investigational Site

Manhasset, NY United States
  Connect »

GSK Investigational Site

New York, NY United States
  Connect »

GSK Investigational Site

Allentown, PA United States
  Connect »

GSK Investigational Site

Dallas, TX United States
  Connect »

GSK Investigational Site

Seattle, WA United States
  Connect »

GSK Investigational Site

Clermont-Ferrand, France
  Connect »

GSK Investigational Site

Grenoble Cedex 9, France
  Connect »

GSK Investigational Site

Basingstoke, United Kingdom
  Connect »

GSK Investigational Site

Edgbaston, United Kingdom
  Connect »

GSK Investigational Site

Glasgow, United Kingdom
  Connect »

GSK Investigational Site

Liverpool., United Kingdom
  Connect »

GSK Investigational Site

Manchester, United Kingdom
  Connect »

GSK Investigational Site

Middlesbrough, United Kingdom
  Connect »

GSK Investigational Site

Newcastle-upon-Tyne, United Kingdom
  Connect »

GSK Investigational Site

Nottingham, United Kingdom
  Connect »

GSK Investigational Site

Plymouth, United Kingdom
  Connect »

GSK Investigational Site

Sheffield, United Kingdom
  Connect »